MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells
- PMID: 11178989
- DOI: 10.1006/bbrc.2001.4339
MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells
Abstract
Overexpression of the oncoprotein MDM2, a negative feedback regulator of p53, is often observed in breast cancer tissue and cell lines, particularly in those which express estrogen receptor alpha (ERalpha). In this study, we report a novel function of MDM2, i.e., as a positive regulator of ERalpha. This function does not involve p53. MDM2 overexpressing clones derived from the breast cancer cell line, MCF-7 cells, showed a remarkable growth advantage only in estradiol supplemented conditions, and this profile coincided with increased transcriptional activity of ERalpha in these cells. Though p53 has been reported to be an inhibitor of ERalpha function, p53 protein in MDM2 overexpressing clones was more abundant than in the parental cells. When ERalpha was exogenously expressed in p53-null cells, its activity was enhanced by coexpression of MDM2. Mammalian two-hybrid assays and GST pull-down assays indicated that MDM2 could interact with ERalpha. These results indicate that MDM2 is a direct activator of ERalpha function, and suggest such a role for MDM2 in ERalpha-positive breast cancer.
Similar articles
-
p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.Cancer Res. 2003 May 15;63(10):2616-23. Cancer Res. 2003. PMID: 12750288
-
Estrogen receptor protects p53 from deactivation by human double minute-2.Cancer Res. 2000 Apr 1;60(7):1810-4. Cancer Res. 2000. PMID: 10766163
-
Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.Breast Cancer Res Treat. 2010 Jul;122(2):395-407. doi: 10.1007/s10549-009-0581-0. Epub 2009 Oct 22. Breast Cancer Res Treat. 2010. PMID: 19847644
-
Cell cycle regulatory functions of the human oncoprotein MDM2.Mol Cancer Res. 2003 Dec;1(14):1009-16. Mol Cancer Res. 2003. PMID: 14707284 Review.
-
Tumor suppressor p53 and estrogen receptors in nuclear-mitochondrial communication.Mitochondrion. 2014 May;16:26-37. doi: 10.1016/j.mito.2013.10.002. Epub 2013 Oct 29. Mitochondrion. 2014. PMID: 24177747 Free PMC article. Review.
Cited by
-
Estrogen signaling and the DNA damage response in hormone dependent breast cancers.Front Oncol. 2014 May 14;4:106. doi: 10.3389/fonc.2014.00106. eCollection 2014. Front Oncol. 2014. PMID: 24860786 Free PMC article. Review.
-
Stabilization of estrogen receptor α by USP37 contributes to the progression of breast cancer.Cancer Sci. 2023 May;114(5):2041-2052. doi: 10.1111/cas.15613. Epub 2023 Mar 10. Cancer Sci. 2023. PMID: 36221793 Free PMC article.
-
Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RLIM in breast cancer.Cancer Res. 2009 Jan 1;69(1):128-36. doi: 10.1158/0008-5472.CAN-08-1630. Cancer Res. 2009. PMID: 19117995 Free PMC article.
-
The UPS: a promising target for breast cancer treatment.BMC Biochem. 2008 Oct 21;9 Suppl 1(Suppl 1):S2. doi: 10.1186/1471-2091-9-S1-S2. BMC Biochem. 2008. PMID: 19007432 Free PMC article. Review.
-
Predictive modeling of moonlighting DNA-binding proteins.NAR Genom Bioinform. 2022 Dec 2;4(4):lqac091. doi: 10.1093/nargab/lqac091. eCollection 2022 Dec. NAR Genom Bioinform. 2022. PMID: 36474806 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
